Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
National Institute of Environmental Health Sciences (NIEHS) |
---|---|
Information provided by: | National Institute of Environmental Health Sciences (NIEHS) |
ClinicalTrials.gov Identifier: | NCT00015483 |
Hematotoxicity is caused by a number of agents such as a benzene by-product called hydroquinone and the antitumor agent doxorubicin. This is a basic research study, conducted using normal human donors, of mechanisms involved in hematotoxicity and of the protective response of human hematopoietic progenitor cells to hematotoxic agents. Tumor necrosis factor exposure protects these cells from a subsequent exposure to hematotoxic agents. The alteration of gene expression in these cells caused by tumor necrosis factor is being studied. Additionally, the tumor necrosis factor-induced biochemical pathways involved in protection of human hematopoietic progenitor cells will be studied.
Condition |
---|
Cancer |
Study Type: | Observational |
Study Design: | Random Sample |
Official Title: | Hematotoxic Effects of Benzene and Doxorubicin |
Ages Eligible for Study: | 18 Years to 55 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Study ID Numbers: | 5020-CP-001 |
Study First Received: | April 20, 2001 |
Last Updated: | September 1, 2006 |
ClinicalTrials.gov Identifier: | NCT00015483 |
Health Authority: | United States: Federal Government |
Hematotoxicity Benzene Bone Marrow |
Doxorubicin |